Aapro M S
Genolier Cancer Center, Switzerland.
Oncology (Williston Park). 1997 Aug;11(8 Suppl 8):46-9.
Docetaxel (Taxotere) and vinorelbine (Navelbine) have both demonstrated activity as single agents for the treatment of patients with metastatic breast cancer and non-small-cell lung cancer. With 100 mg/m2 of docetaxel administered as a 1-hour intravenous infusion once every 3 weeks, projected median survival in previously untreated and treated patients with non-small-cell lung cancer is reported to be approximately 9 months. In addition, response rates have ranged from 23% to 36% and 17% to 21% in these respective patient populations. Preliminary studies indicate that in previously untreated patients with non-small-cell lung cancer, vinorelbine provides a survival benefit that is greater than best supportive care and similar to that of platinum-based chemotherapeutic regimens. Investigation into the use of these agents in combination is supported by synergy shown in preclinical models, nonoverlapping side-effect profiles, and the schedule independence of docetaxel. Preliminary results from phase I and II combination studies are encouraging, and no neurotoxicity has been observed. Based on these data, further study into the combined use of docetaxel and vinorelbine in patients with non-small-cell lung cancer is warranted.
多西他赛（泰索帝）和长春瑞滨（诺维本）均已显示出作为单一药物治疗转移性乳腺癌和非小细胞肺癌患者的活性。以每3周1次、1小时静脉输注100mg/m²多西他赛治疗，据报道，既往未接受过治疗和已接受过治疗的非小细胞肺癌患者的预计中位生存期约为9个月。此外，在这些相应的患者群体中，缓解率分别为23%至36%和17%至21%。初步研究表明，在既往未接受过治疗的非小细胞肺癌患者中，长春瑞滨提供的生存获益大于最佳支持治疗，且与铂类化疗方案相似。临床前模型显示的协同作用、不重叠的副作用谱以及多西他赛给药时间的独立性，支持了对这些药物联合使用的研究。I期和II期联合研究的初步结果令人鼓舞，且未观察到神经毒性。基于这些数据，有必要进一步研究多西他赛和长春瑞滨联合用于非小细胞肺癌患者的情况。
